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Abstract
The objective of this study was to investigate the preventive effects of rosemary leaf extract (RE)
and its active components on prevention of weight gain and associated metabolic disorders in
high-fat-fed mice; determine the effective doses of the chief compound in RE to reduce weight
gain and hyperglycemia; and try to understand the underlying anti-obesity mechanism. For this
purpose, commercial RE with 45% carnosic acid (CA) was enriched with CA to 80%. Animals
were given low-fat diet (LFD), high-fat diet (HFD), high fat with 0.50% RE (enriched with 45%
CA, RE#1), high fat with 0.28% w/w RE (enriched with 80% CA, RE#2H), and high fat with
0.14% w/w RE (enriched with 80% CA, RE#2L) for 16-week periods. Physiological and
biochemical parameters were monitored. Treatment with CA, dose dependently, induced a
significant reduction of weight and fat mass gain which it was associated with an increase of
fecal lipid excretion. Likewise, hypercholesterolemia, fasting glycaemia, and insulin resistant
were improved by CA treatments. Hepatic triglyceride levels, correspondingly, were decreased
in CA-treated mice. In conclusion, the results from this study demonstrate that consumption of
the RE that is rich in CA, dose dependently can limit weight gain induced by a high-fat diet and
protect against obesity-related metabolic disorders.
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CHAPTER 1
Introduction
Metabolic syndrome is a global emerging health concern. Endocrine and metabolic
diseases are problematic modern human disorders, primarily in the United States and other
countries with extensive nutrition. Their risk factors have capability of acting as an indicator
for many chronic diseases such as cardiovascular disease, kidney disease, and type 2 diabetes
mellitus (Woolston, Tu, Baxter, & Gilthorpe, 2012). Effective strategy against obesity and
hyperglycemia, two important risk factors of metabolic syndrome, is critical for reducing the
possibility of cardiovascular disease. Side effects of the currently existing methods such as
pharmacological and surgical interventions have impeded their usefulness. This awareness has
led to nonstop effort to discover effective agents such as new medications as well as natural
products extracted from herbal plants. Many active compounds extracted from herbal plants
possess healing values, i.e. antiobesity and hypoglycemic activity, etc.(Joyal, 2004). Using
botanicals provides safer pharmaceutical and nutritious products for customers and less
expensive approval process under the guidelines of to the US Food and Drug Administration
(M. Romo Vaquero et al., 2012).
Therefore, the present research has been performed to investigate effects of REs and
their major active component CA, dose dependently, in high-fat-fed mice.
1.1 Metabolic Syndrome and Obesity
Metabolic syndrome is a combination of conditions related to obesity that includes
excess central adiposity, insulin resistance, hyperlipidemia, and hypertension. The syndrome
may affect more than 5% of the elderly in the United States and even higher percentages in
different racial groups around the world (Golden, Robinson, Saldanha, Anton, & Ladenson,
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2009). A rapid increase in metabolic syndrome prevalence and severity has paralleled the
dramatic increase in rates of obesity and type 2 diabetes (F. M. Elisa Fabbrini, B. Selma
Mohammed, Terri Pietka, Nada A. Abumrad, Bruce W. Patterson, Adewole Okunade, Samuel
Klein, 2009).
Metabolic syndrome profoundly affects the quality of life and represents a life-long
burden on a patient’s social support system. To the extent that the component risk factors of the
metabolic syndrome contribute to cardiovascular disease with long time treatment, the financial
impact on the Medicare program may be substantial. Alyssa et al. estimated that people with
metabolic syndrome cost $259 more per month than those comparable individuals without the
syndrome (Alyssa B. Schultz., 2009). Meanwhile another research showed the medical costs are
20% higher rates among patients with the metabolic syndrome than among those without in 10
years (Curtis et al., 2007). The unsustainable growth in health care spending in the United States
increases importance of prevention investment. However, costs to the society related to excess
metabolic disorders, component risk factors, and their complications are not limited to health
care costs. Losses attributable to reduced job productivity such as absenteeism, disability, labor
productivity reduction, have also been found to be associated with these health risks. Studies
suggest that the costs of lost productivity from metabolic syndrome and its complications could
far go above the costs of medical care (Schultz AB, 2009).
Today, obesity is a global concern because of its fast growing rates and its comorbidities,
such as type 2 diabetes and cardiovascular disease. In addition, obesity is also associated with
increased risk of various cancers, including endometrial, breast, and colon cancer (Strain et al.,
2012). It has been predicted that obesity will be the number one health problem globally by the
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year 2025 and thought to be overtaking cigarette smoking soon to become the leading cause of
death in the United States.
1.2 Adipose Tissue and Obesity
Obesity is related to an abnormal large amount of body fat, specifically adipose tissue.
The major component of adipose tissue, adipocyte, plays an important role as an energy storage
site in the form of triglyceride (Brännmark et al., 2013). Adipose tissue maintains the free fatty
acid levels and triglycerides in circulation. It has been demonstrated that an amplified amount of
adipose tissue related to obesity is caused by increase in the number of adipocytes, hyperplasia,
or by increase in the size of adipocyte which it is called hypertrophy (Wolfram, Wang, &
Thielecke, 2006).
Visceral adipose tissue is around the internal organs and releases free fatty acids and
adipokines into the portal vein for direct transport to the liver. This role makes visceral adipose
tissue count as an important and independent predictor of metabolic risk factors for coronary
heart disease, particularly diabetes and dyslipidemia (F. M. Elisa Fabbrini, B. Selma
Mohammed, Terri Pietka, Nada A. Abumrad, Bruce W. Patterson, Adewole Okunade, Samuel
Klein, 2009; S. S. Elisa Fabbrini, Samuel Klein, 2010). Moreover, the results from a study on
human subjects with metabolic syndrome demonstrated that an increase in visceral adipose
tissue is associated with glucose tolerance reduction, insulin resistance, and increased very-lowdensity lipoprotein– triglyceride secretion (Adiels et al., 2006). These findings, have led to the
thought that visceral adipose tissue is in charge for many of the metabolic defects associated with
abdominal obesity (Bays, Blonde, & Rosenson, 2006). In conclusion, a reduction in visceral fat
has become a key therapeutic goal in the controlling of obesity and metabolic syndrome.
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1.3 Dietary Prevention of Weight Gain and Metabolic Syndrome by Rosemary and
Rosemary Constituents
In the last decade, nutritional, pharmacological, and surgical strategies have been
developed to prevent the metabolic effect of high fat diet. According to the adverse side effect of
the pharmacological and surgical intervention, nutritional intervention maybe is the safest and
most cost effective option for those who have moderate metabolic syndrome. Hence, nutritional
intervention, in particular the use of herbs in the prevention of metabolic syndrome and its
complications has been growing tremendously during these years.
Rosemary (Rosmarinus officinalis) is an herb widely used in the flavoring of food, folk
medicine, cosmetics, and phytopharmacy. Previous studies have revealed that the biological
activities of rosemary (Rosmarinus officinalis L.) are credited to its components such as CA,
carnosol, rosmarinic acid, and ursolic acid content (Debersac, Vernevaut, Amiot, Suschetet, &
Siess, 2001; Del Campo, Amiot, & Nguyen-The, 2000; Ibarra et al., 2011; Karpinska, Borowski,
& Danowska-Oziewicz, 2000; Koga, Nomoto, Shibata, & Yoshino, 2006; Kosaka & Yokoi,
2003; Lo, Liang, Lin-Shiau, Ho, & Lin, 2002; Moreno, Scheyer, Romano, & Vojnov, 2006;
Moss, Cook, Wesnes, & Duckett, 2003; Naemura, Ura, Yamashita, Arai, & Yamamoto, 2008;
Pengelly et al., 2012; Perez-Fons, Garzon, & Micol, 2010; Steiner et al., 2001; Takahashi et al.,
2009). One of the most interesting food additive compound in rosemary is CA through it strong
antioxidant effect. CA is an abietane diterpene found in the popular Labiatae herbs sage and
rosemary and it is considered as an originator of other diterpenoid constituents in the herbs.
Many studies have determined the antioxidant activities of CA and related diterpenes such as
carnosol and rosmanol. The results have shown CA has the most powerful antioxidant power
among these diterpenes. Easily oxidization of CA has been related to its typical o- diphenol
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structure (Bozin, Mimica-Dukic, Samojlik, & Jovin, 2007; Jordan, Lax, Rota, Loran, &
Sotomayor, 2012; Masuda et al., 2002; Moreno et al., 2006).
CA has a good safety profile which does not pose a health concern for the European
Food Safety Authority (European Food Safety Authority, 2008). The Panel notes that the margin
between the not observable adverse effect level of carnosol plus CA, as calculated in 90 days rat
studies, is equivalent to 20–60 mg/Kg body weight (mpk), and the mean intake of CA rich REs is
estimated to be 500–1500 mg/day in adults and 182–546 mg/day in pre-school children
(European Food Safety Authority, 2008). It is assumed that at the concentrations are used as a
food additive, CA levels would not cause significant hepatotoxicity. There are couple in vivo
researches studies have been published for evaluating weight loss and antiadipogenic effects with
different doses of CA. Even the capacities of rosemary to control obesity and hyperglycemia
have been observed in vivo, whether these effects are due to CA or other constituents is currently
unknown. Moreover, little is known about the safety, and the mechanisms of CA at doses that are
needed to achieve therapeutic effect for weight loss and control hyperglycemia. It is important to
identify the major active compound in rosemary, and to confirm its efficacy and safety in
relevant biological models before conducting clinical trial research.
1.4 Specific Aims and Central Hypothesis of the Research
The prevalence of metabolic syndrome is dramatically increased in developing and
industrialized countries (Miranda, DeFronzo, Califf, & Guyton, 2005). Excess metabolic
disorders, component risk factors, and their complications affect the health care costs and also to
the social productivity (Alyssa B. Schultz., 2009). Obesity is reaching epidemic and an
established risk factor for various comorbidities, such as type 2 diabetes, metabolic disorders and
cardiovascular disease worldwide (Golden, Robinson, Saldanha, Anton, & Ladenson, 2009).

7
Although, Rosemary (Rosmarinus officinalis L.) extracts is shown to be an effective treatment to
prevent the metabolic effect of high fat diet (Ibarra et al., 2011), it is not fully understood
whether the antiobesity and antidiabetic effect is due to CA or other active components.
Moreover, the mechanisms of action and effective therapeutic doses for its active components
are also unclear.
Our long-term goal is to develop rosemary and its active components as a safe and
effective approach for high-fat diet-induced metabolic syndrome. The objectives of this study
were to identify the economic way to prepare CA enriched RE from the commercial RE (45%
CA), and determine the preventive effects of RE (45% CA), and its active compound on weight
gain, glucose levels and lipid homeostasis in high-fat-fed mice; identify the effective doses of the
active component and RE to reduce weight gain and type 2 diabetes; and understand the
underlying mechanisms. These studies provided useful information as to the effective doses of
CA enriched RE on the risk for chronic disease, and they were also served as foundation for
understanding the important mechanisms by which CA may help prevent this disease.
Central hypothesis: The central hypothesis was that CA as the major active component
of rosemary can dose dependently prevent the development of metabolic syndrome induced by
high fat diet.
We expected to test our hypothesis by pursuing the following three specific aims:
1.

To determine whether CA is the major active component in RE.

2.

Investigate the dose depending effects of dietary CA enriched RE on high fat diet
induced metabolic syndrome.

3.

Investigate the underlying fat limiting mechanisms of RE and CA.
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CHAPTER 2
Literature Review
2.1 Obesity, Type 2 Diabetes, and Metabolic Syndrome
Obesity is a health condition that is characterized by a body mass index (BMI), 30 or
higher which is associated to an abnormal large amount of body fat, specifically adipose tissue
(J. James, 2004). The rates of obesity have increased dramatically in the United States in the last
20 years and even more rapidly in the last 10 years. The studies have shown consumption of a
high fat diet and sedentary lifestyle lead to obesity. Numerous studies in the last 50 years have
suggested a significant relation between obesity and the incidence of diseases such as type 2
diabetes, cardiovascular disease, and hypertension (W. P. James, Rigby, & Leach, 2006).
However the mechanism(s) responsible for the interrelationship among obesity, insulin
resistance, and hypertriglyceridemia is not fully known.
A study by Fabbrini et.al demonstrated that obesity reflected as an increased storage of
triacylglycerides in adipose tissues (S. S. Elisa Fabbrini, Samuel Klein, 2010). Their data show
that increased visceral adipose tissue and intrahepatic triglyceride level are important risk factors
for the metabolic complications associated with obesity, particularly insulin resistance and
dyslipidemia. There is ample evidence that an impaired non-esterified fatty acid metabolism
could contribute to the insulin-resistant state observed among individuals with visceral obesity
(Despres & Lemieux, 2006). Moreover, modifications in tissue fatty acid transport could be
involved in the pathogenesis of ectopic triglyceride accumulation by redirecting plasma fatty
acid uptake from adipose tissue toward other tissues (F. M. Elisa Fabbrini, B. Selma
Mohammed, Terri Pietka, Nada A. Abumrad, Bruce W. Patterson, Adewole Okunade, Samuel
Klein, 2009).
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Obesity is considered as one of the primary risk factors for type 2 diabetes in many
studies. It has been demonstrated that obesity is often accompanied by chronic, low-grade
inflammation that is characterized by increased release of inflammatory cytokines such as tumor
necrosis factor alpha (TNF-α), monocyte chemotactic protein-1 (MCP-1) and adiponectin in
blood and accumulation of macrophages in the adipose tissue and the liver (Curat et al., 2006;
Kawano & Arora, 2009; Kim & Lee, 2012). A recent study has also showed that MCP-1 plays an
important role in insulin resistance that causes type 2 diabetes (Kim & Lee, 2012). As a result,
inflammation reduction may be an important strategy in reducing the risk of obesity and
associated type 2 diabetes (Bruun, Lihn, Pedersen, & Richelsen, 2005) . Both the altered nonesterified fatty acid metabolism and the endocrine function hypotheses imply that visceral
adipose tissue is causally involved in the pathophysiology of the metabolic syndrome that is
often found in patients with visceral obesity. Therefore, visceral adipose tissue is an important
risk factor for obesity related metabolic disorders and its reduction has become a significant aim
in obesity management (F. M. Elisa Fabbrini, B. Selma Mohammed, Terri Pietka, Nada A.
Abumrad, Bruce W. Patterson, Adewole Okunade, Samuel Klein, 2009).
Type 2 diabetes is a heterogeneous disorder. It has been estimated that the risk of
developing type 2 diabetes is higher in those who are severely obese rather than of healthy
weight (93-fold in women and 42-fold in men) (Dixon et al., 2011). In 2013, the total prevalence
for either type of diabetes was 25.8 million Americans, 8.3% of the population in United States,
which approximately 90-95% of them have type 2 diabetes (Association, 2013).
Type 2 diabetes is generally characterized as failure to appropriate respond to insulin
(Insulin resistance). As a result, glucose access to key organs such as skeletal muscle is reduced
and blood glucose levels remains high. This uncontrolled condition could cause blindness, nerve
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damage, kidney disease, cardiovascular disease, and other potentially fatal complications (Bose
et al., 2008; Mlinar, Marc, Janez, & Pfeifer, 2007). Muscle, liver, and the adipose tissue are three
major organs in the body that are affected by insulin resistance. Under normal conditions, these
tissues produce a response to elevated level of blood glucose, via the action of insulin. Elevated
blood glucose can cause insulin release into the bloodstream from the β-cells in the pancreas.
Phosphoinositide-3-kinase (PI3K) signaling cascade that activates the protein AKT is the major
response of insulin binding to cell surface receptors in the muscle and the adipose tissue.
Translocation of the glucose transporter type 4 (GLUT4) from the cytosol to the cell surface and
consequently, glucose entrance to cell is caused by activation of AKT that play an important role
in returning blood glucose to normal levels (Bose et al., 2008). Inhibition of gluconeogenic
enzymes and suppression of hepatic glucose output in the liver is also activated by the PI3K
cascade (Mlinar et al., 2007).
Under insulin resistant condition, the response of muscle, adipose tissue, and liver to
glucose uptake is reduced regardless of insulin availability in blood glucose. Therefore, the
pancreas is producing more insulin to maintain normal blood glucose with the eventual
development of pancreatic β-cell dysfunction. In the result, achieving glycemic control is a
critical metabolic goal because hyperglycemia contributes to the progression of type 2 diabetes
by adversely affecting both β-cell function and insulin sensitivity (Mlinar et al., 2007).
Metabolic syndrome is a global emerging health concern (Vinluan, Zreikat, Levy, &
Cheang, 2012). This syndrome has been defined by clinical symptoms such as insulin resistance,
dyslipidemia, central obesity, hypertension, impaired glucose tolerance or diabetes mellitus
(Miranda et al., 2005). Current research show individuals with metabolic syndrome have much
higher risk for cardiovascular diseases. Based on the National Cholesterol Education Program’s
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Adult Treatment Panel III (NCEP/ATP III) guidelines, a little more than one-third of the adults
in the United States (34% of the US population) could be characterized as having metabolic
syndrome (Ervin, 2009). Adults aged between 20 to 29 year have increased prevalence of 6.7%
and ages from 60 to 69 have prevalence of 43.5% (Golden et al., 2009). According to
NCEP/ATP III, a diagnosis of the metabolic syndrome is made when three or more of the risk
factors shown in table 1 are present (Ervin, 2009). Metabolic syndrome increased with age but
increased even more dramatically as BMI increased.
Table 1
ATP III clinical identification of the metabolic syndrome
Risk factor Defining level
Abdominal obesity (waist circumference) Men >102 cm (>40 in), Women >88 cm (>35 in)
Triglycerides

≥150 mg/ dL

HDL cholesterol

Men <40 mg/dL , Women <50 mg/dL

Blood pressure

≥135/≥85 mm Hg

Fasting glucose

≥100 mg/dL

Metabolic disorders, including obesity and diabetes, can be linked to an increased
oxidative stress (Ibarra et al., 2011). Administration of plant extracts with antioxidant ability can
decrease this stress (Seifried, Anderson, Fisher, & Milner, 2007). These plant-based compounds
could stimulate expression of the nuclear peroxisome proliferator-activated receptors (PPAR).
One of these receptors, nuclear peroxisome proliferator-activated receptor gamma (PPARγ)
directs genes that control fatty acid uptake and storage, inflammation and glucose homeostasis
which are transcription factors that regulate energy homeostasis. This transcription factor is
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known to promote a late-stage adipocyte marker and play important roles in the regulation of
lipid metabolism (M. Romo Vaquero et al., 2012).
2.2 Rosemary and Its Effects on Obesity and Related Metabolic Syndrome
Diet rich in fruits, vegetables and herbs has been known for decades that may help to
reduce cardiovascular and metabolic complications, but there is limited knowledge about
components of these foods that confer health benefits (Miranda et al., 2005). Biological activities
of plant-derived phenolic compounds have been recently considered as an excellent source to
control these diseases, however, there are still unsolved safety and efficacy issues in humans
(Beltrán-Debón et al., 2011).
Recently, rosemary is one of the appreciated sources for its health benefits including
hepatoprotective, antibacterial, antithrombic, antiulceratic, diuretic, antidiabetic, antinociceptive,
anti-inflammatory, antitumor and antioxidant properties (al-Sereiti, Abu-Amer, & Sen, 1999;
Borras Linares et al., 2011; Ibarra et al., 2011; Karamadoukis, Shivashankar, Ludeman, &
Williams, 2009). Rosemary, Rosmarinus officinalis L. (Lamiaceae), is an aromatic evergreen
shrubby herb highly distributed in the Mediterranean region (Jalali-Heravi, Moazeni, & Sereshti,
2011). Traditionally, rosemary has been used as a food flavoring spice and folk medicine in
curing or managing of a wide range of diseases such as respiratory disorders, stomach problems
and inflammatory diseases (Borras Linares et al., 2011). The water decoction of rosemary leaves
has been traditionally used to treat diabetic patients, especially in the western part of Turkey,
without much scientific evidence of its utility (Bakirel, Keles, Ulgen, & Yardibi, 2008).
Rosemary is a good source for microelements and vitamins such as iron, calcium, and vitamin
B6.
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Application of rosemary has been verified by European Food Safety Authority as a
natural preservative in foods and beverages. Rosemary can be found in northern African
countries such as Morocco, and Tunisia, in southern Europe countries especially in Spain,
France, Italy, the area of former Yugoslavia, Iran and also in America (Jalali-Heravi et al., 2011).
Based on the studies in various cell line systems and animal models, different
mechanisms of action have been proposed for the observed beneficial effects of RE, which could
be attributed to its components. Though it is not clear which component is the major agent
against obesity and metabolic syndrome (Baba et al., 2005; Bel-Rhlid et al., 2009; Hosny,
Johnson, Ueltschy, & Rosazza, 2002).
2.2.1 Major components in rosemary. Up to now, almost one hundred components in
RE have been identified by using HPLC–MS or GC-MS (Borras Linares et al., 2011; JalaliHeravi et al., 2011). These compounds belong mainly to the classes of phenolic diterpenes (CA,
carnosol, rosmadial, rosmanol and its isomers epirosmanol and epiisorosmanol), flavonoids
(genkwanin, homoplantaginin, scutellarein and cirsimaritin), triterpenes (ursolic acid, oleanolic
acid,betulinic acid,botulin), and phenolic acids (rosmarinic acid, caffeic acid) (Bel-Rhlid et al.,
2009; Borras Linares et al., 2011; Razborsek, Voncina, Dolecek, & Voncina, 2007). The levels
of rosemary compounds vary significantly based on the parts of the plant (leaves, stems, sepals,
petals, seeds, roots), seasonal variation, and the extraction method (Almela, Sanchez-Munoz,
Fernandez-Lopez, Roca, & Rabe, 2006; Razborsek, 2011).
The principal bioactive components of the extracts are the phenolic diterpenes
specifically CA (molecular formula C20H28O4) (Fig. 1). It is a constituent of the species Salvia
and Rosmarinus where it is mainly to be found in the leaves of rosemary and sage. Dried leaves
of rosemary contain between 1.5 – 2.5% CA. Carnosol, rosmanol, epirosmanol and
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methoxyepirosmanol are often present in less percentage than CA and also in some extent a
result of degradation of CA with antioxidant properties (Thorsen & Hildebrandt, 2003). Some
studies suggested that CA is therefore the only phenolic diterpene present in native state in
rosemary and, accordingly, has the sole right to be called a natural product (Song et al., 2014).
The molecule of CA has two physic-chemical properties; the molecule contains
apparently polar functions, such as carboxylic acid and phenol function. On the other hand, the
remainder of its skeleton, made up essentially of hydrocarbons, provides a relatively nonpolar
character by contrast with all other phenolic compounds, such as the flavonoids or
hydroxybenzoic which are present in abundance in plant.
.
OH
HO
HOOC

H
(4aR,10aS)-1,2,3,4,4a,9,10,10a-octahydro-5,6-dihydroxy-7-isopropyl-1,1-dimethylphenanthrene4a-carboxylic acid

Figure 1. Molecular structure of carnosic acid
CA can be oxidize to carnosol by oxidation, and carnosol can degrade further to produce
other phenolic diterpenes (Saenz-Lopez, Fernandez-Zurbano, & Tena, 2002). The highly
oxidized abietane diterpenes rosmanol, isorosmanol, and dimethyl isorosmanol are formed from
CA by dehydrogenation and the participation of activated oxygen (Bonoli, Pelillo, & Lercker,
2003) (Fig.2). Some methods for the preparation of CA by extraction have been proposed in
literatures and patents in which the processes are long, complex. Due to economic reasons, these
methods cannot be applied to an industrial process (Herrero, Plaza, Cifuentes, & Ibanez, 2010;
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Okamura, Fujimoto, Kuwabara, & Yagi, 1994). Aeschbach et al. invented a preparation process
according to these two physic-chemical properties of CA, extraction by using first nonpolar then
polar solvent. This process gives a residue contains between 65 to 90% CA (Robert Aeschbach,
1993).
Several different analytical methods have been developed in order to determine the
content of CA in samples with comparatively simple matrices. The high-performance liquid
chromatography (HPLC) coupled with UV and/or MS detection has been the most widely used
methods (Sanchez-Escalante, Djenane, Torrescano, Beltran, & Roncales, 2001; Haixia Yan et al.,
2009).
This phenolic diterpene, and its phenolic hydroxyl group is easily oxidized and degraded
under alkaline conditions (pH > 7) and is stable at acid conditions (pH < 4). CA can easily be
converted into carnosol by air oxidation (Mulinacci et al., 2011; Schwarz, Ternes, &
Schmauderer, 1992). However, the results of a study by Yan et al., 2009, show carnosol was not
found in rat plasma samples after intragastric administration of CA in their study, indicating that
CA could not be oxidized in vivo to generate carnosol as a metabolite (Haixia Yan et al., 2009).
There have been only few reports for CA bioavailability and tissue distribution in rats (Doolaege,
Raes, De Vos, Verhe, & De Smet, 2011; Haixia Yan et al., 2009), and no information for its
metabolic profiles. Analysis of CA in rat plasma after intravenous and intragastric administration
by Yan et al. reported a bioavailability of 65% (Haixia Yan et al., 2009). Doolaege et al.
investigated the absorption of CA into the bloodstream after oral administration in rats. CA was
found in the rat’s intestinal content, liver and muscle tissue of abdomen and legs. It was found
that CA in vivo present in its free form and that the main elimination route of CA is the fecal
route (Doolaege et al., 2011).
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Figure 2. Formation of abietane diterpenes in rosemary plants (Munne-Bosch, Schwarz, &
Alegre, 1999).
2.2.2 Antiobesity and antidiabetic effects of rosemary active components
2.2.2.1 In-vitro studies. Takahashi et al. found that CA and carnosol inhibited the
differentiation in mouse preadipocytes (3T3-L1 cells) into adipocytes. In this study, these
compounds induced phase 2 enzymes which are involved in metabolism of glutathione (GSH),
activated nuclear factor E2-related factor-2 (Nrf2) and antioxidant-response element (ARE), and
increased intracellular GSH. However, it remains unknown as yet which pathway mainly
contributes to the inhibition by CA (Takahashi et al., 2009).
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In 2012, Cui et al. demonstrated that abietane-type diterpenes from rosemary possessed
moderate diacylglycerol acyltransferase (DGAT) inhibitory activity (Long Cui, 2012).
Triglycerides (TG) are one of the main forms of stored energy. Excess accumulation of TG in
certain tissues leads to serious diseases such as obesity, type 2 diabetes, and
hypertriglyceridemia. TG synthesis has been assumed to occur primarily through (DGAT),
which catalysis the final and only committed step in the glycerolphosphate pathway. DGAT
activity can be promising strategy for the potential treatment of Type 2 diabetes, obesity and
other related diseases that contain metabolic syndrome. In this study additionally, carnosol, one
of the major components, exhibit a very effective inhibition property on de novo intracellular
triglyceride synthesis on human hepatocyte HepG2 cells (Long Cui, 2012). CA and carnosol
were used in an inhibitory test for pancreatic lipase activity in vitro. The inhibitory effect of CA
was comparable to that of orlistat, and carnosol showed stronger lipase inhibitory activity than
CA (Ninomiya et al., 2004). Tu et al. investigated the mechanisms of RE on metabolism in
HepG2 cells. They found that RE significantly increased glucose consumption and glycolysis in
HepG2 cells and activated the AMP-activated protein kinase (AMPK) and PPAR signaling
pathways. They concluded that rosemary potential increased liver glycolysis and fatty acid
oxidation by activating AMPK and PPAR pathways (Tu, Moss-Pierce, Ford, & Jiang, 2013).
2.2.2.2 In-vivo studies. It has been reported that RE has significant beneficial effect on
metabolic disorders, such as obesity, hyperlipidaemia and hyperglycaemia in many animal
models. Harach et al. (Harach et al., 2010) demonstrated male C57BL/6J mice fed on a HFD (60
Kcal% fat) supplemented with RE (200mg/kg BW per day, not 20mg/kg BW per day) for 50
days were protected against weight gain induced by the HFD. Their results show RE (contains
2.5% CA, 4% rosmarinic acid and 5.6% carnosol) was able to reduce fat mass gain and liver TG
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content, and increase fecal fat excretion in compare to control group. The effects of RE might be
related to the inhibition of pancreatic lipase activity (demonstrated in vitro) and caused a
limitation of lipid absorption. In this study, the dose of CA (5mg/kg BW) was lower than that
(20mg/kg BW) in the study of Ninomiya et al.(Ninomiya et al., 2004). They also found that
administration of 20 or 200 mg/kg BW of RE in mice fed a HFD did not improve glucose
tolerance, fasting plasma glucose or fasting plasma insulin level (Harach et al., 2010).
Moreover, Ibarra et al. reported that 16-week dietary intake of RE with 20% CA
(500mg/kg BW/day) reduced the body weight gain, as well as epididymal fat weight in HFD-fed
(44·92% Kcal fat) male C57BL/6J mice. The plasma cholesterol level was decreased by the RE
administration, but there was no significant difference in plasma TG and non-ester fatty acid
(NEFA) levels. RE treatment in this study was associated with increased fecal fat excretion. RE
supplement was able to inhibit pancreatic lipase activity and activate PPAR-γ in vitro (Ibarra et
al., 2011). Together, with reports of Ninomiya et al. (Ninomiya et al., 2004) and Harach et al.
(Harach et al., 2010), the effects of limiting lipid absorption is a potential mechanism by which
RE limits weight gain, at least partially.
In another study, 64-day administration of RE (0.5% w/w, supplemented in standard
chow diet) with 40% CA also reduced body weight gain and improved the plasma lipids profile
in obese (fa/fa) and lean (fa/+) female Zucker rats through inhibiting of gastric lipase (M. Romo
Vaquero et al., 2012). However, the decrease of levels of TG and cholesterol was only
significant in the lean female rats. There were the same results of reducing body weight and
increasing fecal weight as those of Harach et al. (Harach et al., 2010) and Ibarra et al. (Ibarra et
al., 2011) studies. In this study, the levels of CA, carnosol and methyl carnosate in the
gastrointestinal tract with RE supplement were quantified, and the highest levels of CA and
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carnosol were found in the stomach. The methylated derivative of CA was found to be the most
abundant in the jejunum, ileum, and liver, may be due to the action of cathecol-O-methyl
transferases (COMTs) in the intestine and liver. The highest and most significant inhibition of
lipase activity (70-80%) was found in the stomach of the RE treated rats, which is responsible for
the reduction in the absorption of dietary fat.
Few studies demonstrated positive effects of RE on improving the lipid profile in some
animal models fed with hypercholeterolemic diet (Afonso et al., 2013; Al Sheyab, Abuharfeil,
Salloum, Bani Hani, & Awad, 2011). Al Sheyab et al. (Al Sheyab et al., 2011) reported that the
levels of plasma total cholesterol, low density lipoprotein (LDL), and TG were significantly
reduced by rosemary water soluble extract administration (100 mg/kg BW) for 15 days in female
BALB/c mice. In another study, an aqueous extract (AQ, 70 and 140 mg/kg BW) and nonesterified phenolic fraction (NEPF, 70 and 140 mg/kg BW) were studied in rats by gavage for 4
weeks. AQ contains 1.87% rosmarinic acid and NEPF contains 5.71% CA. However, only the
AQ at 70 mg/kg significantly reduced the serum total cholesterol and non-HDL-c levels, maybe
due to the amount of total phenolic compounds found in AQ was almost twice as much as in
NEPF. Both AQ and NEPF have significant antioxidant activities in different tissues, but neither
was able to ameliorate the alterations in the hypercholesterolemic diet-induced fatty acid
composition in the liver (Afonso et al., 2013).
Limited number of studies applied CA alone. CA was carried out in HFD fed mouse
model for its anti-obese effects by Ninomiya et al. In this study, CA was given orally to male
ddY mice fed HFD (40 Kcal % fat) for 14 days. The results show CA (20 mg/kg BW/day)
limited body weight gain and the accumulation of epididymal fat weight. Interestingly, although
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with three different doses of CA (5, 10, 20 mg/kg BW/day), only 10 mg/kg BW/day of CA could
suppress the serum TG elevation. Further studies are needed to clarify this observation.
Wang et al. analyzed the effects of CA (0.05% w/w, added in standard chow diet) in male
ob/ob mice (obese leptin-deficient mice). After administration of CA for 5 weeks, the weight
gain of mice was significantly inhibited and the visceral adiposity was reduced by CA
administration. Meanwhile, the serum TG and cholesterol levels were reduced and the glucose
tolerance was improved significantly. CA also had significantly protective effect by inhibiting
hepatic fat accumulation and decreasing serum alanine aminotransferase (ALT) levels. CA also
inhibited adipocyte hypertrophy of white adipose tissue (WAT) by decreasing adipocyte size (T.
Wang et al., 2011). In good according with the results of Ninomiya et al. (2004), CA has lipidlowering and body weight reducing effects, and is recognized to be a novel therapeutic agent for
obesity and obesity-related diseases. The further mechanism was studied by Wang et al. (Wang
et al., 2012). They found the preventing effects of CA on hepatocyte lipid accumulation was
associated with repressed PPARγ levels and activated EGFR, MAPK, AMPK and ACC, which
regulate lipid metabolism. They concluded that EGFR/MAPK signaling pathway plays an
important role in the effects of CA. In this study, insulin resistance itself was not actually
examined and unexpectedly the fasting glucose in CA+ mice was higher than control group.
In a previous study in Dr. Sang’s lab, fifty mice were categorized into 3 groups according
to the following design: negative control group on a low-fat diet (10 kcal% fat) (n=20); control
group on a high-fat diet (60 kcal% fat) (n=20); and a high-fat diet with 0.5% of CA enriched RE
(40% CA) (n=10) (unpublished data). This study showed that 0.5% of RE with 40% CA in the
diet limited weight gain and hyperglycemia in mice that were fed a HFD over 16- week. The RE
reduced body weight gain by 54.9 %, omental fat gain by 38.9%, and retroperitoneal fat gain by
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25.1%. It also reduced fasting blood glucose levels by 71.2% and plasma insulin levels by 92.5%
after 16-week . Moreover the incidence of fatty livers has also been inhibited.
Currently, substantial scientific interest is focused toward the effects of rosemary on
obesity and obesity-related diseases. With regard to the above-mentioned, RE has been shown to
be effective on body weight gain, fat mass gain, lowering serum lipid and glycemia in some
animal models. However, form and mechanism of action of them have not been fully understood.
The previous studies in this area provide a foundation for future studies that will identify the
mechanistic bases for the metabolic effects of them. More in vivo studies are warranted to find
weather CA is the major active component in rosemary to prevent obesity and related metabolic
syndrome, and to further understand the underlying mechanism.
2.3 The High-Fat Diet-Fed Mouse as an Appropriate Model for Obesity and the Metabolic
Syndrome
To understand metabolic syndrome and nutritional interventions related to its prevention
or treatment, it is important to have appropriate animal models. Due to different technical skills,
the availability of equipment, and the substances, it is unlikely metabolic experiments would be
accomplished in the exact same way in different laboratories. Therefore the results will hardly be
consistent from one laboratory to another. However, certain parameters can be standardized,
regardless of where tests are conducted. This will help researchers the necessary information for
interpreting results that might differ as a result of differences in methodology. One of the
important parameter in metabolic studies is choosing appropriate animal model. Differences in
these parameters can affect the results found from metabolic tests. Obesity, adipose tissue,
glucose tolerance, Insulin resistant, and lipid levels are important elements in the metabolic
disorders studies. One hypothesis for growing of metabolic syndrome in humans is the
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possibility that our regulatory systems become overwhelmed by high-fat high-density foods,
which have become increasingly available over the past 20–30 years. We chose high-fat dietinduced obesity and diabetes mouse model because among environmental factors, the high-fat
content of the typical Western diet is considered a major cause of obesity and related type 2
diabetes. This mouse model was originally introduced by Surwit et al. in 1988 (Collins, Martin,
Surwit, & Robidoux, 2004). They demonstrated that the C57BL/6J mouse would develop severe
obesity, hyperglycemia, and hyperinsulinemia if weaned onto a high-fat diet.
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Table 2
In vivo studies showing the effects of Rosemary on obesity and diabetes
Year

References

Treatment

Al-Hader,
A. A.,
Hasan, Z.
A., & Aqel,
M. B.
“Hyperglycemic and
insulin
release
inhibitory
effects of
Rosmarinu
s
officinalis.”
2004 Ninomiya,
K.,
Matsuda,
H.,
Shimoda,
H.,
Nishida,
N.,
Kasajima,
N.,
Yoshino,
T.,
Yoshikawa
, M.
“CA, a new
class of
lipid
absorption
inhibitor
from sage.”

Volatile
oil extract
of
Rosemary

1994

CA

Dosage
/admini
stration
route
i.m.
25mg/k
g BW,
6h

Oral,
5, 10
and
20mg/k
g BW

Animal
model

Time

Outcomes

Conclusion

Alloxaninduced
male
diabetic
rabbits

6h

-Serum glucose:
Increased ~17%,
Increased in
normal rabbits
after IPGTT
-Serum
insulin:~30%Decr
eased after
IPGTT 30min in
normal rabbits

The volatile
oil extract
has
significant
hyperglyce
mic and
insulin
release
inhibitory
effects.

High
14 d
fat(Olive
oil)-fed
male ddY
mice

-BW Reduced by
~7%
-Serum TG: No
difference for
14days, but
reduced at 2, 4,
6h after
administration
- Serum glucose:
level was reduced
only at 10mg/kg
dose for 14days
treatment and at
5, 10mg/kg at 2,
4, 6h,
-increased weight
of Epidydimal fat
pad.
- Inhibited
pancreatic lipase
activity.

Inhibited
pancreatic
lipase
activity.
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Cont.
2006 Koga, K.,
Nomoto,
K., Shibata,
H., &
Yoshino,
K.
“Effects of
50%
ethanol
extract
from
rosemary
on [alpha]glucosidase
inhibitory
activity and
the
elevation
of plasma
glucose
level in
rats, and its
active
compound.
“
2007 Nusier, M.
K.,
Bataineh,
H. N., &
Daradkah,
H. M.
”Adverse
effects of
rosemary
on
reproductiv
e function
in adult
male rats.”

Rosemary
50%
ethanol
extract

Rosemary
70%
ethanol
extract

As
drinkin
g water
at
0.01%
dose
Maltose
or
sucrose
was
orally
adminis
terewit
h or
without
rosemar
ydistilled
extract,
to mice
at a
dose of
20
mg/mo
use.
As
drinkin
g water
at 250
and 500
mg/kg
BW

STZinduced
male ddY
diabetic
mice

Serum glucose:
Decreased

Male
SpragueDawley
rats

-Body weight: No
difference
-Serum TG: No
difference
-Serum
cholesterol: No
difference
- Serum glucose:
No difference
-No difference in
ALT and AST

63da
ys

Rosemary
may play a
role in
controlling
dietary
glucose
uptake in
the small
intestinal
tract,
because of
RE’s effects
of inhibiting
aGlucosidase
activity, In
part.
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Cont.
2008 Bakirel, T.,
Keles, O.
U., Ulgen,
S. G., &
Yardibi, H.
“In vivo
assessment
of
antidiabetic
and
antioxidant
activities of
rosemary
in alloxandiabetic
rabbits.”

Rosemary
95%
ethanol
extract

Oral,
50,
100,
200
mg/kg
BW,
Normal
, acute
at 1, 2,
6h, and
at
Subacut
e blood
samples
were
collecte
d at 1st,
3rd,
5th, and
8th
days
after
each
treatme
nt.

Alloxaninduced
diabetic
adult
rabbits of
either sex

7day
s


-Body weight:
increased
- Serum glucose:
Acute: decreased
only in 200mg/kg
at 2 and 6h.
Subcute:
decreased in 8th
day with
100mg/kg and
decreased in
200mg/kg from
3rd day.
-Serum insulin:
Acute: increased
only in 200mg/kg
at 2 and 6 h.
Subcute:
increased in 8th
day with
100mg/kg and
increased in
200mg/kg from
3rd day
- Normal:
decreased in 100
mg/kg after 2h of
oral
administration
and recovered at
6h. Decreased in
200 mg/kg after 2
and 6h. No
change in insulin.
And decreased in
100 mg/kg at 6h
and in200mg/kg
at 2, 6h after
OGTT. No
insulin change.

Hypoglycae
mic action
was
observed to
be dose
dependent.
The RE
exerts
remarkable
hypoglycae
mic and
antihypergly
caemic
activity due
to its
possible
multiple
effects
involving in
pancreatic
and extrapancreatic
and
antioxidant
mechanism.
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Cont.
2010 Harach, T.,
Aprikian,
O.,
Monnard,
I., Moulin,
J.,
Membrez,
M.
“Rosemary
leaf extract
limits
weight gain
and liver
steatosis in
mice fed a
high-fat
diet.”
2011

RE(contai
ns 4%
rosmarinic
acid, 2.5%
CA, and
5.6%
carnosol)

Wang, T.,
CA
Takikawa,
Y., Satoh,
T.,
Yoshioka,
Y., Kosaka,
K.,
Tatemichi,
Y., &
Suzuki, K.
“CA
prevents
obesity and
hepatic
steatosis in
ob/ob
mice.”

Oral,
20
mg/kg
BW
and
200mg/
kg
BW(0.2
5% and
0.025%
W/W
diet)

HFD fed
male
C57BL/6
J mice

Oral,
0.05%
(w/w)

Male
obese
leptindeficient
(ob/ob)
mice

50
days

-Body weight:
Reduced by
~11% with
200mg/kg dose
-Liver TG:
Reduced with
200mg/kg
-Serum TG: No
difference
-Serum
cholesterol: No
difference
-Serum glucose:
No difference
-Serum insulin:
No difference
- RE induced a
higher fecal fat
excretion
5
-Body weight:
week Decreased
s
- Serum TG:
Reduced by ~
60%
- Serum
cholesterol:
Reduced by
~24%
- Liver TG: N
-Serum glucose:
Reduced by
~18%
-Serum insulin:
Decreased by
47%
- No difference in
food intake.
-Plasma FFA
decreased.

The results
suggest that
RE did not
regulate
glucose
homeostasis
in dietinduced
obesity mice
but RE
induced a
higher
faecal fat
excretion
inhibited
pancreatic
lipase
activity in
vitro.
CA
inhibited
adipocyte
hypertrophy
of WAT by
a decrease
of adipocyte
size.
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Cont.
2011 Ibarra, A.,
Cases, J.,
Roller, M.,
ChiraltBoix, A.,
Coussaert,
A., &
Ripoll, C.
“CA-rich
rosemary
leaf extract
limits
weight gain
and
improves
cholesterol
levels and
glycaemia
in mice on
a high-fat
diet.”
2012 Romo
Vaquero,
M., YanezGascon
“Inhibition
of gastric
lipase as a
mechanism
for body
weight and
plasma
lipids
reduction
in Zucker
rats fed a
RE rich in
CA.”

RE (20%
CA)

Oral,
500mg
/kg BW

HFD fed
male
C57BL/6
J mice

16-Body weight:
week Decreased
- Serum TG: No
difference
- Serum
cholesterol:
Reduced
-Serum glucose:
Decreased
- Serum insulin:
No difference
- RE increased
fecal total lipid
excretion and
fecal energy
excretion, and
decreased
pancreatic lipase
activity.

Antihyperglyce
mic activity
in a HFD
mouse
model.

RE (40%
CA)

Oral,
0.5%
(w/w)
(RE
350700
mg/kg;
CA,
140 280
mg/kg )

Female
Zucker
lean(fa/+
) and
obese
(fa/fa)
rats

64
days

-RE
significantly
inhibited
gastric
lipase
activity in
the
stomach ,
which may
cause a
moderate
reduction of
fat
absorption.

-Body weight:
Reduced by 15%
-Serum TG :
Decreased in lean
rats, but no
difference in
obese rats
-Serum
cholesterol:
Decreased in lean
rats, but no
difference in
obese rats
-Liver TG: No
difference
-Serum glucose:
No difference
-Serum insulin:
reduced in leans.
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Table 2
Cont.
2012

2012

Al Sheyab,
F. M.,
Abuharfeil,
N.,
Salloum, L.
“The effect
of
rosemary
plant
extracts on
the
immune
response
and lipid
profile in
mice.”
Aljamal, A.
“Effects of
rosemary
on lipid
profile in
diabetic
rats.”

RE (water
soluble
extract)

Oral,
100mg/
kg BW
d

High
cholester
ol diet
fed
female
BALB/c
mice

15da
ys

- Serum TG:
Reduced
-Serum
cholesterol:
Reduced
- LDL decreased
and HDL
significantly
increased by RE
supplement.

RE hot
water
extract

Oral,
550
mg/mo
use/day

STZinduced
male
albino
rats

4
- Serum TG :
week Decreased by
s
24%
- Serum
cholesterol:
Decreased by
22% .
- Serum glucose:
Decreased
by20%LDL
decreased by 27%
and HDL
increased by18%.

Hypolipide
mic activity
of RE

-RE had a
Hypoglyce
mic effect
and
improved
the lipid
profile.
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Table 2
Cont.
2013 Milessa S
Afonso, A.
M. d. O. S.,
Eliane BT
Carvalho,
Diogo P
Rivelli,
Sílvia BM
Barros,, &
Marcelo M
Rogero, A.
M. L.,
Rosângela
P Torres
and Jorge
ManciniFilho.
“Phenolic
compounds
from
Rosemary
attenuate
oxidative
stress and
reduce
blood
cholesterol
concentrati
ons in dietinduced
hyperchole
sterolemic
rats.”

Rosemary
aqueous
extract
(AQ,
contain
1.87%
Rosmarini
c acid)and
nonesterified
phenolic
fraction
(NEPF,
contain
5.71%
CA)

AQ 70
and 140
mg/kg
BW,
NEPF 7
and 14
mg/kg
BW

Hypercho 4
lesterole week
mic diet
s
fed male
Wistar
rats

-Body weight: No
difference
-Serum TG: No
difference
-Serum
cholesterol: Only
decreased in
70mg AQ/kg
dose.
-No difference in
food intake.
-70mg AQ/kg
dose decreased
non-HDLcholesterol.
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CHAPTER 3
Methodology
3.1 Materials
Rosemary Extract: The RE with 45% CA used in this study was purchased from China.
Mice: Seventy-five male C57BL/6J mice, aged 5 weeks were purchased from Jackson
Laboratories (Bar Harbor, ME, USA).
- Low-fat diet (10 Kcal%, 4.3 % fat w/w), high-fat diet (60 Kcal%, 35% fat w/w), high
fat with 0.50% w/w RE with 45% CA, high fat with 0.28% w/w RE with 80% CA, high fat with
0.14% w/w RE with 80% CA were made by Research Diets, Inc. (New Brunswick, NJ) (Table
3).
3.2 Experimental Methods
3.2.1 Experiment 1- Preparation of RE with 80% CA and CA (95%) standard. RE
with 80% CA and CA standard were freshly prepared from the RE (45% CA) in our lab.
3.2.1.1 Extraction and isolation. CA was prepared according to the U.S. patent
5,256,700 (Robert Aeschbach, 1993) in our lab with modification (Fig. 3). In brief, 50 g RE
(45% CA) was subjected to column chromatography over silica gel (230-400 mesh, Sorbent
Technologies Inc., Atlanta, GA) and was eluted with a gradient of hexane-acetone (50:2, 50:3,
50:4, 50:5, 0:100; 1000 mL each) to give 5 fractions (Fr. A-E).
Purification of fraction B (23.3g) by reverse phase C18 silica gel medium pressure column
chromatography (35 mm × 400 mm, 60 Å, Sigma) eluted with 75% methanol /water containing
0.05% formic acid, gave four sub fractions (Fr. B1-B4). Fraction B2 (6.85 g) was identified as the
CA enriched fraction (80% CA) by HPLC-MS. In order to get enough samples for the mouse
study, this procedure was repeated five times. For further purification, 5.0 g of fraction B2 was
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loaded to Sephadex LH-20 column chromatography using ethanol as eluent, and only 0.5 g pure
CA (98%) was obtained.
Rosemary extract (45% CA); 50 g
Hexane/ Acetone
Normal phase silica gel column
50:2
Fraction A

50:3

50: 4

Fraction B

Fraction C

50:5
Fraction D

100% Acetone
Fraction E

Methanol/Water (75%)
Reverse phase C18 silica gel column

Fraction B1

Fraction B2; (80% CA); 5 g

Fraction B3 Fraction B4

Ethanol
Sephadex LH- 20 column

Fraction BS1

Fraction BS2; (98% CA); 0.5 g

Figure 3. Separation scheme to prepare RE with 80% CA and purified CA (98%).
3.2.1.2 Analysis of CA by NMR. Nuclear magnetic resonance (NMR) was used for
confirming the CA structure. 1 H and 13 C NMR spectra (analyzed in CDCL3) were recorded on a
Bruker AVANCE 700 MHz spectrometer (Brucker, Silberstreifen, Rheinstetten, Germany).
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3.2.1.3 Analysis of the major components in RE by HPLC/ECD and LC/ESI-MS.
3.2.1.3.1 HPLC/ECD analysis. A high-performance liquid chromatography/ESA
electrochemical detector (HPLC-ECD) (ESA, Chelmsford, MA) consisting of an ESA model 584
HPLC pump, an ESA model 542 autosampler, an ESA organizer, and an ESA CoulArray
detector coupled with two ESA model 6210 four sensor cells, was used in the current study. A
Gemini C18 column (150 × 4.6 mm, 5 μm; Phenomenex, Torrance, CA) was used for
chromatographic analysis at a flow rate of 1.0 mL/min. The mobile phases consisted of solvent A
(30 mM sodium phosphate buffer containing 1.75% acetonitrile and 0.125% tetrahydrofuran, pH
3.35) and solvent B (15 mM sodium phosphate buffer containing 58.5% acetonitrile and 12.5%
tetrahydrofuran, pH 3.45). The gradient elution had the following profile: 5% B from 0 to 3 min;
5 to 55% from 3 to 10 min; 55 to 100% from 10 to 40 min; 100% B from 40 to 45 min; and 5%
B from 45.1 to 50min. The cells were then cleaned at a potential of 1000 mV for 1 min. The
injection volume of the samples was 10 μL. The eluent was monitored by the Coulochem
electrode array system (CEAS) with potential setting at -50, 100, 200, 300, 400, 500, and 600
mV.
3.2.1.3.2 LC/ESI-MS analysis. LC/MS was carried out with a Thermo-Finnigan Spectra
System, which consists of an Accela high-speed MS pump, an Accela refrigerated auto sampler,
and an LTQ Velos ion trap mass detector (Thermo Electron, San Jose, CA) incorporated with an
electrospray ionization (ESI) interface. A Gemini C18 column (150 × 4.6 mm, 5 μm;
Phenomenex, Torrance, CA) was used for separation at a flow rate of 200 µL/ min. The column
was eluted with 100% solvent A (5% aqueous methanol with 0.2% acetic acid) for 3 min,
followed by linear increases in B (95% aqueous methanol with 0.1% acetic acid) to 60 % from 3
to 8 min; then to 75 % from 8 to 30 min, to 82 % from 30 to 48 min; and then with 100% from
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48 to 55 min. The column was then re-equilibrated with 100 % A for 5 min. The injection
volume was 10 µL for each sample. Nitrogen gas was used as the sheath gas and auxiliary gas.
The collision-induced dissociation (CID) was conducted with an isolation width of 2 Da and
normalized collision energy of 35 for MS2 and MS3. The mass range was measured from 50 to
1000 m/z. Data acquisition was performed with Xcalibur version 2.0 (Thermo Electron, San Jose,
CA, USA).
3.2.2 Experiment 2 –Animal study and biological analysis. All animal experiments
were conducted according to protocol (ID: 12-012) approved by the Institutional Animal Care
and Use Committee at the North Carolina Research Campus (NCRC) in Kannapolis.
3.2.2.1 Animal and diets. All mice were housed on a 12-hour light/ dark cycle in a
temperature-controlled environment during 1-week acclimatization, with ad libitum access to
water and diet. After acclimatization, mice were randomized into 5 groups (n=15). Each group
was fed the following experimental diet for 16-week : low-fat diet (10 Kcal%, 4.3 % fat w/w,
LFD), high-fat diet (60 Kcal%, 35% fat w/w, HFD), high fat with 0.50% RE (enriched with 45%
CA, RE#1), high fat with 0.28% w/w RE (enriched with 80% CA, RE#2H), high fat with 0.14%
w/w RE (enriched with 80% CA, RE#2L) (Table 4).
Body weight and drink intake were measured weekly. Food intake was recorded every
day. Signs of abnormality and possible toxicity were monitored. At the end of the study, liver,
omental fat, and retroperitoneal fat were harvested, rinsed, and weighed. In addition, for
measuring fecal lipid levels, from each group 5 mice were placed at a metabolic cage and 24hour fecal samples were collected at week 16. All samples were stored at -80 ºC. Fasting blood
glucose was measured at 0, 10, and 16-week of treatment. Food was removed 6 h prior to blood
glucose measurements. Blood was collected from the tail vein, and glucose levels were measured
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with One Touch Ultra 2 glucose monitor (Life scan, Inc. Milpitas, CA, USA). Mice were fooddeprived for 8 hours and sacrificed by isophorone inhalation after 16-week of treatment. Whole
blood was obtained by cardiac puncture. Blood samples were centrifuged at 5,000 rpm for 15
min.
3.2.2.2 Biochemical analysis of plasma samples. Biochemical levels were measured
using commercial kits. Plasma alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) activities were colorimetrically measured using Infinity ALT and AST Reagent provided
by Thermo Scientific (Waltham, MA). Plasma triglyceride and cholesterol concentrations were
measured by Infinity Triglyceride and Infinity Cholesterol Reagent (Thermo Scientific),
respectively. Plasma free fatty acid was determined with a Free Fatty Acid Quantification Kit
(BioVision, Milpitase, CA). Insulin levels were determined using Ultrasensitive Insulin ELISA
kit (ALPCO, Salem, NH). Glucose levels in tail vein blood samples were measured using an
OneTouch Ultra2 Blood Glucose Meter (LifeScan, Milpitase, CA).
3.2.2.3 Determination of lipid concentrations in liver. Quantitative assay of lipids was
conducted by measuring triglyceride, cholesterol and FFA concentrations in the liver. In brief:
hepatic lipids are extracted by homogenizing liver tissue in chloroform using 1% Triton X-100.
The organic extracts were air dried, vacuumed, and dissolved in Trition X-100. Triglyceride,
cholesterol, and FFA concentrations in extracts were determined using commercial kits (see
Blood Biochemical Markers).
3.2.2.4 Body composition. A nuclear echo magnetic resonance imaging whole-body
composition analyzer (Echo MRI System, Kannapolis, NC, USA) was used to assess body fat
and lean mass in conscious mice. One cage was chosen from each group in week 15.
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3.2.2.5 Fecal lipid measurements. The feces harvested during a 24-hour period, were
collected at week 16; frozen at -80°C; and pulverized. Total lipids were extracted from 100 mg
of dried feces using the following method (Folch, Lees, & Stanley, 1957): The feces were
cleaned and dried for 24 hours by freeze dryer, incubated with 2 mL of chloroform-methanol
(2:1) for 30 min at 60°C with constant agitation, and then centrifuged. Water (1 mL) was added
to the supernatant, and following vortexing, phase separation was induced by low-speed
centrifugation (2,000 rpm for 10 min). The lower chloroform phase was then removed and
transferred to a new tube, and the sample was evaporated to dryness by nitrogen evaporator and
weighed.
3.2.2.6 Statistical analysis. The data from the in vivo studies were expressed as mean ±
standard deviation (x ± SD). One-way analysis of variance (ANOVA one-way, Newman-Keuls
multiple comparison test) and student t-test were performed to compare groups using Sigma Plot
11.0 (2008) (Systat Software, Inc.). Statistical significance was considered at p<0.05.
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Table 3
Composition of the experimental diets.
LFD

HFD

Macronutrient
g%

Kcal %
20
70
10
100

g%

HFD + RE#2H
(0.28%)
g%
kcal
%
26.2
20
26.3
20
34.8
60
100
5.23

HFD + RE#2L
(0.14%)
g%
kcal
%
26.2
20
26.3
20
34.8
60
100
5.24

Protein
Carbohydrate
Fat
Total
Kcal/g

19.2
67.3
4.3

Ingredient
Casein/80 mesh
L-Cystine

g
200
3

kcal
800
12

g
200
3

kcal
800
12

g
200
3

kcal
800
12

g
200
3

kcal
800
12

g
200
3

kcal
800
12

Corn starch
Maltodextrin 10
Sucrose

506.2
125
68.8

2024.8
500
275.2

0
125
68.8

0
500
275.2

0
125
68.8

0
500
275.2

0
125
68.8

0
500
275.2

0
125
68.8

0
500
275.2

Cellolose,BW2
00

50

0

50

0

50

0

50

0

50

0

Soybean oil
Lard

25
20

225
180

25
245

225
2205

25
245

225
2205

25
245

225
2205

25
245

225
2205

Mineral
mix,S10026
D Calcium
Phosphate
Calcium
carbonate
Potassium
citrate, 1 H2o

10

0

10

0

10

0

10

0

10

0

13

0

13

0

13

0

13

0

13

0

5.5

0

5.5

0

5.5

0

5.5

0

5.5

0

16.5

0

16.5

0

16.5

0

16.5

0

16.5

0

Vitamin mix,
V10001
Cholin Biartrate

10

40

10

40

10

40

10

40

10

40

2

0

2

0

2

0

2

0

2

0

RE#1
RE#2

0
0

0
0

0
0

0
0

3.9
0

0
0

0
2.18

0
0

0
1.09

0
0

Dye

0.05

Total

1055.05

3.85

26.2
26.3
34.9

Kcal
%
20
20
60
100

HFD + RE#1
(0.5%)
g%
kcal
%
26.1
20
26.2
20
34.7
60
100
5.22

5.24

0.05
4057

773.85

0.05
4057

777.75

0.05
4057

776.03

0.05
4057

774.94

4057
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CHAPTER 4
Results
4.1 Experiment 1- Characterization of the Major Components in REs.
4.1.1 Structure elucidation of purified CA from commercial RE by NMR. The
structure of CA was identified using NMR techniques and confirmed by comparison of its NMR
data with those already published (Masuda, Inaba, & Takeda, 2001; H. Yan et al., 2009).
Multiplicities are indicated by s (singlet), d (doublet), and brd (broad doublet) (Table 4, Fig. 4 A,
B).
4.1.2 HPLC/ECD and LC/MS analysis.
4.1.2.1 Determination of the purity of CA standard by HPLC/ECD. CA standard was
purified by the combination of different column chromatography techniques in our lab. The
purity of CA standard was obtained based on the analysis of peak areas generated automatically
from CoulArray Data Station 3.00 (ESA Biosciences, MA). In a same manner, the content of CA
in RE was also quantified.
4.1.2.2 LC/MS analysis. LC/MS analysis of the prepared REs revealed a total of three
major diterpene phenolic compounds present in the extracts. The compounds were characterized
by their retention times, UV-Vis and mass spectrum, and identified by comparison with
published data (H. Yan et al., 2009) or commercial standards. Figure 5 A shows, the
chromatographic profile of the commercial RE with 45% CA. CA was shown in the middle and
the highest peak. After extraction of the commercial product, the figure 5 B shows the
chromatographic profile of the RE with 80% CA. LC/ESI-MS results demonstrated that for CA
related compounds, the neutral loss of a CO2 molecule (44 Da) was regarded to be a
characteristic fragmentation pathway (María Romo Vaquero et al., 2013; Song et al., 2014). Take
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CA (Peak Ⅰ, at retention time of 36.5 min) for example, the MS spectrum of CA exhibited and
deprotonated ion at m/z 331 [M-H]- (data not shown), corresponding to a molecular weight of
332 amu, MS2 spectrum (Fig. 5D) of the precursor ion at m/z 331 [M-H]- afforded a predominant
product ion at m/z 287, generating by the neutral loss of a CO2 (44 Da) from the carboxyl
moiety. Likewise, the other two major peaks (Peak Ⅱ and Ⅲ, at retention times of 32.7 and 40.1
min, respectively) were tentatively identified as carnosol and 12-O-methyoxy CA by comparing
their MS/MS data with the reference data from literature(Song et al., 2014). The stability of
extracts was tested by monitoring the content of CA using HPLC-DAD-MS/MS. The levels of
CA in the experimental diets remained stable throughout the study period.
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Table 4
NMR spectra data of CA
CA
position

δH multi (J)

δC

1
2

1.63 m
: 1.90 m
: 2.39 m
2.86 m

41.9
18.9

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

1.78 m
: 1.52 m
: 1.60 brd (11.6)
: 1.34 m
: 3.32 brd (13.9)

6.57 s
3.21 m
1.23 d (7.0)
1.23 d (7.0)
1.04 s
0.93 s

34.4
34.4
53.9
20.3
31.5
129.0
122.1
48.7
142.1
141.4
133.7
119.4
27.2
21.7
22.2
32.6
22.5
182.4
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Figure 5. TIC chromatograms of commercial RE (A), CA enriched RE (B), and MS/MS
(negative) spectra of peak Ⅰ(C), Ⅱ(D)and Ⅲ(E).
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4.2 Experiment 2- Animal Study and Biological Analysis
4.2.1 Effects of REs on body and organ weight and food intake in mice fed a high-fat
diet. Body weight between the HFD and LFD groups began to differ significantly after the first
week of treatment (p<0.01). Likewise, body weight between the HFD and the three RE treated
groups started to differ significantly (p<0.05) after the first week of experiment (Fig. 6). At the
end of the study, LFD group had 58% less weight gain than HFD. Weight gain for all treatment
groups (RE#1, RE#2H and RE#2L) were less than that of HFD at 48, 52 and 32% ( p<0.05) at
the end of the study, respectively (Fig. 7).
After 16-week treatment, LFD group had 72% mesenteric fat, 70% perirenal fat, 56%
total fat and 57 % liver weight less than HFD group. The three treated groups (RE#1, RE#2H,
and RE#2L) had 67, 69 and 54 % (p<0.05) less than HFD group in mesenteric fat; 41, 50 and 26
% less than HFD group in perirenal fat; 23.5, 32 and 5 % (p<0.05) less than HFD group in total
fat , 54, 57and 53 % less than HFD group in liver weight, respectively. No significant changes
were observed between groups in epididymal fat (Table 5). An obvious difference between the
mouse abdominal cavities has been observed at the necropsy room.
The above results were further supported by the MRI results. The figures generated from
the MRI demonstrate that the weight gain reduction by RE#1 and RE#2H groups are due to
decrease the fat mass (Fig. 8).
The HFD was very soft and easily crushed and dumped into the cage. Therefore, it is not
possible for us to accurately measure the food intake even we tried to measure it every day. Most
of the literature studies reported that between RE treated group and HFD group there was no
significant difference in food intake(Harach et al., 2010; T. Wang et al., 2011). However, it is
unclear to us how they could measure the food intake in an accurate way.
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Figure 6. Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA (RE#1),
0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) on body weight of
mice during 16-week experiment. Values are means, with standard deviations represented by
vertical bars. Dis similar letters are significantly different at the P<0.05 level, n=15.
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35

b

Weight gain(g)

30
d

25
c

20

c

a

15
10
5
0

LFD

HFD

RE#1

RE#2H

RE#2L

Figure 7. Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA (RE#1),
0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) on weight gain after
16-week. Values are means, with standard deviations represented by vertical bars. Values with
different letter are significantly different at the P<0.05 level, n=15.
Table 5
Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA (RE#1), 0.28% RE
with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L), on weight parameters (mesenteric
fat, perinenal fat, epidididymal , total fat and liver after 16-week.
Parameter

LFD

HFD

RE#1

RE#2H

Re#2L

Mesenteric fat

0.48 ± 0.15

1.71 ± 0.24

0.55 ± 0.21

0.54 ± 0.13

0.78 ± 0.22

Perirenal fat

0.48 ± 0.21

1.58 ± 0.33

0.93 ± 0.28

0.79 ± 0.31

1.16 ± 0.24

Epidididymal fat

1.16 ± 1.16

1.54 ± 1.54

2.21 ± 2.21

1.96 ± 1.96

2.63 ± 2.63

Total fat

2.13 ±0.82

4.84 ± 0.46

3.7 ± 1.14

3.3 ± 1.12

4.59 ± 1.12

Liver weight

1.18 ± 0.26

2.78 ± 0.6

1.27 ± 0.15

1.19 ± 0.14

1.3 ± 0.27



The results are expressed as the mean± SD (n=15)

45

60
b
50

d

Weight (g)

c

c

a

40
30
20
10

0
LFD

A

25

HFD

RE#1

RE#2H

b

Total fat (g)

20

d

15
10

RE#2L

c

c

RE#1

RE#2H

a

5
0
B

LFD

HFD

RE#2L

46

90

% of body weight
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Figure 8. Body composition results of Eco-MRI. The Results of the total weight (A), total fat
(B), lean mass% of the body weight (C) and fat mass% of the body weight (D) after 16-week of
treatment by LFD, HFD, RE#1, RE#2H and RE#2L. Values are mean ± SD. Values with
different letter are significantly different at the P<0.05, n=5.
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4.2.2 Effects of RE on serum biochemical parameters. After 16-week of treatment,
total plasma cholesterol level rose significantly in the HFD group compared with LFD animals.
Plasma cholesterol in LFD compare to HFD is 49% less; in treatment groups, (RE#1, RE#2H
and RE#2L) are 19, 34 and 18% less than HFD, respectively (Fig. 9). However, Plasma
triglyceride and plasma free fatty acids in the HFD group compared with LFD animals are not
significantly different (Fig. 10, Fig. 11).
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c
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d

140
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c

a

100
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40
20
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LFD

HFD

RE#1

RE#2H

RE#2L

Figure 9. Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA (RE#1),
0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) on plasma cholesterol
after 16-week. Values are means, with standard deviations represented by vertical bars, P<0.05,
n= 6.
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Figure 10. Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA (RE#1),
0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) on plasma triglyceride
after 16-week. Values are means, with standard deviations represented by vertical bars, n= 6.
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Figure 11. Effects of low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA (RE#1),
0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) on plasma free fatty
acid after 16-week. Values are means, with standard deviations represented by vertical bars, n=
6.

49
Total glucose levels in LFD group are 21% less than those in HFD group. Mice in
treatment groups (RE#1, RE#2H, and RE#2L) experienced 15, 22 and 17 % plasma glucose
levels (p<0.001) less than those in HFD group (Fig. 12 A). Fasting blood glucose levels in all the
groups were recorded at week 0, 10, and 16 as reported in Figure 12A.
Animals in the LFD group had normal fasting blood glucose level after the 16-week
treatment (160.73±22.72 mg/dl at Week 0; 126.10±20.54 mg/dl at Week 10; 171.6±21.76 mg/dl
at Week 16). In contrast, HFD animals increased fasting blood glucose levels progressively from
the beginning of the study (146.73±21.54 mg/dl) until Week 16 (221.66±28.40 mg/dl).
In the RE-treated groups, fasting blood glucose rose 19.36% in RE#1, 26.31% in
RE#2H, and 17.53% in RE#2L (178.73±22.22 md/dl , 163.33±20.70 md/dl, 182.8±24.67 md/dl ,
p<0.001 ) less than those in HFD mice at the end of the study. There is no significant difference
between blood glucose levels between the two of the treatment groups (RE#1 and RE#2H) and
the LFD group after 16 week.
Figure 12B shows the levels of fasting plasma insulin at the end of the study, week 16.
Reduced fasting plasma insulin levels was significantly different between LFD and HFD, and
also between treatment groups (RE#1, RE#2H, Re#2L) and HFD group (p<0.001). Insulin level
in LFD compare to HFD is 69% less; in treatment groups (RE#1, RE#2H and RE#2L) are 66, 59
and 50% less than HFD, respectively. There is no significant difference of the fasting plasma
insulin levels between two of the treatment groups (RE#1 and RE#2H) and LFD group after 16
week.
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Figure 12. (A) Fasting blood glucose levels in low fat diet (LFD), high fat diet (HFD), 0.5% RE
B

with 45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L)
treated mice at week 0, 10, and 16. (B) Fasting plasma insulin levels in LFD, HFD, RE#1,
RE#2H and RE#2L treated mice after 16-week study. Values are mean ± SD, * = P<0.05, n= 6.

51

4.2.3 Changes in liver weight, incidence of fatty liver, and plasma ALT and AST
levels. After 16-week of treatment, the average liver weight reached 1.18±0.26 g in the LFD
group, 2.78 ±0.60 g in the HFD group, and less liver weight 54.1, 57 .21 and 53.11% in RE#,
RE#2H, Re#2L compare to HFD group(P<0.05) ( Fig. 13).
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Figure 13. Liver weight in low fat diet (LFD), high fat diet (HFD), 0.5% RE with 45% CA
(RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L) groups after
the 16-week study. Values are mean ± SD, * = P<0.05, n= 6.
Liver triglyceride level in LFD compare to HFD is 85% less; and in treatment groups
(RE#1, RE#2H and RE#2L) are 92, 93 and 78% less than that in HFD, respectively (Fig. 14).
Hepatic cholesterol increased significantly in LFD and all treatment groups compare to HFD
group (P<0.05) (Fig. 15). .Free fatty acid in liver level in LFD compare to HFD is 77% less, in
treatment groups, (RE#1, RE#2H and RE#2L) are 83, 82 and 73% less than HFD, respectively
(Fig. 16).
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Figure 14. Hepatic triglyceride levels in low fat diet (LFD), high fat diet (HFD), 0.5% RE with
45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L)
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treated mice after 16-week study. Values are mean ± SD, * = P<0.05, n= 6.
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Figure 15. Hepatic cholesterol levels in low fat diet (LFD), high fat diet (HFD), 0.5% RE with
45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L)
treated mice after 16-week study. Values are mean ± SD, n= 6.
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Figure 16. Hepatic free fatty acid levels in low fat diet (LFD), high fat diet (HFD), 0.5% RE with
45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L)
treated mice after 16-week study. Values are mean ± SD,* = P<0.05, n= 6.
In addition, plasma ALT levels in LFD, RE#1, RE#2H, RE#2L treated mice were
significantly different compare to the HFD group (P<0.001). In LFD group, plasma ALT level
compare to HFD is 74% less and in treatment groups, (RE#1, RE#2H and RE#2L) are 74, 71 and
76% less than HFD, respectively. There are no significance differences between LFD and the
treated groups (Fig. 17A).
Plasma AST levels in LFD, RE#1, RE#2H, RE#2L animals were significantly different
compare to the HFD group (P<0.05). AST level in LFD compare to HFD is 40% less, in
treatment group, (RE#1, RE#2H and RE#2L) are 47, 49 and 39% less than HFD, respectively.
There are no significance differences between LFD and the treated groups (Fig. 17B).
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Figure 17. Plasma ALT (A) and AST (B) levels in low fat diet (LFD), high fat diet (HFD), 0.5%
RE with 45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA
(RE#2L) groups. Values are mean ± SD, * = P<0.001, n= 6.
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4.2.4 Effect of RE on fecal fat excretion. Animals in HFD group had higher fecal fat
excretion values (2.58±0.41 mg/100 mg) compared with those in LFD group (1.39 ± 0.17
mg/100 mg, P<0.05). Lipid excretion among HFD and animals with three RE treatment groups
were significantly different, RE#1 (5.06 ± 0.82 mg/100 mg, P<0.05), RE#2H (4.09 ± 0.27
mg/100 mg, P<0.05), RE#2 L (3.94 ± 0.49 mg/100 mg, P<0.05) in the last week of the
experiment (Fig. 18).

Fecal total lipid excertion
(mg/100mg faceas)

7

*

6

*

5

*

4
3
2
1
0
LFD

HFD

RE#1

RE#2H

RE#2L

Figure 18. Effects of RE on lipid excretion in low fat diet (LFD), high fat diet (HFD), 0.5% RE
with 45% CA (RE#1), 0.28% RE with 80% CA (RE#2H), and 0.14% RE with 80% CA (RE#2L)
groups. Results are presented as means ± S.D, * = p<0.05, n=3.
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CHAPTER 5
Discussion and Future Research
In this doctoral thesis, we developed column chromatography techniques to prepare RE
with 80% CA from commercial available RE (with 45% CA). Moreover, their capacity to
prevent metabolic disorders, such as obesity, hyperlipidemia, and hyperglycemia in different
dosage was evaluated as well as their limit fat absorption mechanism.
Rosemary is one of the most widely consumed spices worldwide. From its origin in
Southeast Asia and its spread to Europe, rosemary is a well-known and greatly valued medicinal
herb that is widely used in pharmaceutical products and folk medicine as a digestive, tonic,
diuretic. More recently, it was reported that rosemary also possessed anticancer, antioxidant,
antibacterial, and anti-inflammatory activities (Aljamal, 2012; Cheung, Hasman, Tai, & Wu,
2012). However, there is less emphasis on the major responsible compound, effective dosage and
underlying mechanisms of rosemary in management of metabolic diseases and their
complications. Thus, it can be difficult to conclude the health benefits of a major component in
RE to another exclusively on the basis of published data. This study has developed a new method
to prepare CA and its enriched RE (80%), and evaluated their anti-obesity and anti-diabetic
effects with different doses.
5.1 Experiment 1- Preparation of CA and Its Enriched RE
In this experiment, we prepared the CA enriched RE (80%) to identify the impact of CA
and the dose effect of CA on weight gain, blood glucose and lipid hemostasis. There has been
emergent interest in the employment of CA in food industry, for its usefulness as preservatives,
as well as for its beneficial effects on human health (Song et al., 2014). CA, like any molecule of
the catechol (or-tho-diphenol) type, is a reactive compound. It is highly sensitive to oxidation
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and, hence, to all the operations typically carried out to isolate natural substances (extraction,
liquid- liquid separation, chromatographic fraction, etc.) (Khalafi, Rafiee, Shahbak, &
Shirmohammadi, 2013). This characterization of CA during its purification makes it an
expensive component (85$/10 mg from Sigma). The problem addressed by the present
experiment is to provide a process for enriching RE with 80% CA which would be economical
and practical for the current study.
5.2 Experiment 2- Study of the Effect of RE Enriched With CA on Body Weight Gain and
Development of Metabolic Syndrome in HFD Treated C57BL/6J Mice
5.2.1 Long term HFD induces obesity and related metabolic syndrome in the
C57BL/6J mice. In animal studies which demonstrate metabolic syndromes to explore
antiobesity and antidiabetes treatments, the choice of the animal model, diet, and experiment’s
duration are critical points that need to be considered. In the present study we investigated the
effects of the daily consumption of a HFD (60 Kcal % fat) on the development of obesity and
related metabolic syndrome in C57BL/6J mice for 16-week. The results demonstrated that the
HFD caused remarkably increased weight gain, fat accumulation, hyperglycemia, insulin
resistance, and increased liver fat in our animal model. In contrast to the most previous similar
studies dietary induced metabolic disorders models, the C57BL/6J mice phenotype becomes
visible within 3 weeks of starting the HFD.
5.2.2 CA is the major active component in RE. Our data indicate treatment of mice
with 0.5 % w/w RE with 45% CA (~224 mg/Kg BW/day) reduced the gains in weight that were
induced by the HFD, which are only 17.8 and 13.1% more than weight gain in LFD group. It
also significantly lowered total fat tissue weight, hepatic TG, liver weight, fasting plasma insulin,
fasting blood glucose compared with HFD mice. In addition, total fecal lipid content increased
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significantly in RE#1 mice compared with the HFD group. Based on the present study, there was
not any significant difference between the results from RE#1 and RE#2H (~225 mg/Kg
BW/day). Since the quantities of CA contents were equal in these two groups, it appears that the
CA plays an important role against in the metabolic disorders and is the major active compound
in RE. Although various biological activities with preventive nutritional intervention against
metabolic disorders has been developed for RE; nevertheless, the chemical description of applied
extracts in studies, is not always available. Thus, it can be difficult to conclude the health
benefits of a unique compound in RE on the basis of published data. Few studies have been
conducted on CA as an effective compound in rosemary (Ninomiya et al., 2004; T. Wang et al.,
2011). Ninomiya et al. have observed that after 2-week of treatment with 20 mpk of CA alone,
the weight of ddY (Deutschland,Derker, Yoker) mice fell by 7.6% compared with the control
group (HFD 40% w/w fat) and the similar results demonstrated by Wang et al., whereas no
results for fasting blood glucose effect has been observed in both studies. Our results together
with the published data on CA in different animal models indicate that CA is the major active
component in RE for obesity and related metabolic syndrome.
5.2.3 Dose dependent effects of CA enriched RE. The results presented in Chapters 4
show that RE with 80% CA could dose dependently reduce HFD induced obesity and metabolic
syndrome by decreasing weight gain, fat mass accumulation, insulin resistance, and
hypercholesterolemia. Furthermore, total fecal lipid content increased in groups with RE with
80% CA dose dependently, compared with the HFD group. Based on the present study and other
evidences (Harach et al., 2010; Ibarra et al., 2011), limiting lipid absorption in the intestine is a
possible mechanism by which CA prevents weight gain.
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In our study, for the first time, we demonstrated the dose-dependent effect of CA
enriched RE on obesity and related metabolic syndrome in the HFD treated mouse model. At
week 3, the RE treated mice began to experience significant reductions in weight gain. The mice
in both RE#1 and RE#2H groups, which contained the same amount of CA (0.22% of diet w/w),
showed significantly less weight gain than those in the RE#2L group (0.11% of diet w/w) after
14-week treatment. These results are consistent with findings from Ibarra and Harach (Harach et
al., 2010; Ibarra et al., 2011). In addition to its effects on weight gain, our results also
demonstrated that CA significantly reduced elevated cholesterol levels that were induced by the
HFD. Furthermore, they found no difference in serum TG and insulin level between control and
treatment group; when our results demonstrated the reduction in liver TG, serum cholesterol, and
FFA in compare to HFD. These findings demonstrate that CA, due specifically to fat mass
reduction, has anti-obesity effects in vivo. Moreover, in the present study, fasting glycaemia and
plasma insulin level were reduced in animals in the treatment groups dose dependently compared
with the HFD control group. There are limited studies that have evaluated the effect of rosemary
on diabetes. Anti-hyperglycaemic effects can be induced by an ethanolic RE in the alloxan
diabetic rat model (Bakirel et al., 2008), however, there was not any information about RE
compound.
5.2.4 Toxicity. In the present study, chronic consumption of the high and low doses (28%
and 14% of diet w/w) of CA enriched RE for 16-week did not show any toxicity to the treated
mice. In contrast, CA significantly reduced the ALT and AST levels that induced by the high-fat
diet which have not been observed in other studies on CA.
5.2.5 Mechanism of RE enriched with CA on obesity and metabolic syndrome. There
are many mechanisms that have been suggested by previous studies for RE against obesity and
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metabolic syndrome. Some of these studies have been accomplished in vitro such as pancreatic
lipase inhibition (Ninomiya et al., 2004), peroxisome proliferators-activated receptor gamma
(PPARγ) activation, and the differentiation of mouse pre-adipocytes into adipocytes prevention
(Takahashi et al., 2009). Some in vivo studies have investigated the ability of rosemary to control
weight gain and glycaemia (Harach et al., 2010; H. Wang et al., 2011). Vaquero et al. in 2012
demonstrated RE (40% CA) significantly inhibited gastric lipase activity in the stomach, which
may cause a moderate reduction of fat absorption (M. Romo Vaquero et al., 2012). Several
studies have found that limit fat absorption is the key mechanism for RE to limit weight gain
(Harach et al., 2010; Ibarra et al., 2011; Ninomiya et al., 2004). The present study further
confirms this mechanism by observing the increase of fecal fat excretion in RE treated mice.
5.2.6 Future research. The present study and literature studies found that RE could
prevent weight gain and metabolic syndrome induced by HFD treatment. However, it is unclear
whether RE has treatment effect to obese mice. In addition, it is also worthwhile to study the
detail mechanisms that RE limits fat absorption. Furthermore, whether RE has antiobesity effect
in human is another topic of future research.
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